3400-26-8

Basic information

• Product Name: N-methyl-3-nitrobenzamide
• Synonyms: N-methyl-3-nitrobenzamide;BenzaMide, 3-nitro-N-Methyl-
• CAS NO: 3400-26-8
• Molecular Formula: C₈H₈N₂O₃
• Molecular Weight: 180.16072
• Mol File: 3400-26-8.mol

Chemical Properties

• Boiling Point: 357.2 °C at 760 mmHg
• Flash Point: 169.9 °C
• Appearance: /
• Density: 1.272 g/cm³
• Vapor Pressure: 2.76E-05mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: N-methyl-3-nitrobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-3-nitrobenzamide(3400-26-8)
• EPA Substance Registry System: N-methyl-3-nitrobenzamide(3400-26-8)

Safety Data

• Hazardous Substances Data: 3400-26-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
N-methyl-3-nitrobenzamide is utilized as an intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Production:
N-methyl-3-nitrobenzamide also serves as a key intermediate in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural products to enhance crop protection and yield.
Used in Organic Compounds Synthesis:
N-methyl-3-nitrobenzamide is employed as a building block in the synthesis of a wide range of organic compounds, facilitating the creation of novel chemical entities for various applications.
Used in Research and Development:
As a valuable compound in the field of chemistry, N-methyl-3-nitrobenzamide is used in research and development to explore its properties, reactions, and potential applications in different industries.
It is crucial to handle N-methyl-3-nitrobenzamide with care due to its potential hazards if not properly managed and used.

InChI:InChI=1/C8H8N2O3/c1-9-8(11)6-3-2-4-7(5-6)10(12)13/h2-5H,1H3,(H,9,11)

Upstream product

• 88070-48-8 N-methylbenzamide 
• 74-89-5 methylamine 
• 121-90-4 m-nitrobenzoic acid chloride 
• 108-24-7 acetic anhydride 
• 16089-77-3 N-methyl-α-(m-nitrophenyl)nitrone 
• 421-20-5 Methyl fluorosulfonate 
• 619-24-9 3-nitrobenzonitrile 
• 7647-01-0 hydrogenchloride 
• 18370-07-5 3-nitro-benzoic acid-(chloro-methyl-amide) 
• 593-51-1 methylamine hydrochloride 
• 121-92-6 3-nitrobenzoic acid 
• 19499-61-7 methyl-(3-nitro-benzyl)-amine 

Downstream Products

• 18370-07-5 3-nitro-benzoic acid-(chloro-methyl-amide) 
• 69746-32-3 1-methyl-5-(3-nitrophenyl)-tetrazole 
• 25900-61-2 3-amino-N-methylbenzamide 
• 2243-80-3 3-nitrobenzophenone 
• 881589-86-2 N-(cyclohexylmethyl)-3-nitrobenzamide 
• 500701-24-6 3-(5-methyl-1H-tetrazol-1-yl)aniline 
• 865540-80-3 phenyl 3-(5-methyltetrazol-1-yl)phenylcarbamate 
• 40746-64-3 5-methyl-1-(3-nitrophenyl)tetrazole 

Relevant articles and documents

2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase

Renewed interest in covalent inhibitors of enzymes implicated in disease states has afforded several agents targeted at protein kinases of relevance to cancers. We now report the design, synthesis and biological evaluation of 6-ethynylpurines that act as covalent inhibitors of Nek2 by capturing a cysteine residue (Cys22) close to the catalytic domain of this protein kinase. Examination of the crystal structure of the non-covalent inhibitor 3-((6-cyclohexylmethoxy-7H-purin-2-yl)amino)benzamide in complex with Nek2 indicated that replacing the alkoxy with an ethynyl group places the terminus of the alkyne close to Cys22 and in a position compatible with the stereoelectronic requirements of a Michael addition. A series of 6-ethynylpurines was prepared and a structure activity relationship (SAR) established for inhibition of Nek2. 6-Ethynyl-N-phenyl-7H-purin-2-amine [IC50 0.15 μM (Nek2)] and 4-((6-ethynyl-7H-purin-2-yl)amino)benzenesulfonamide (IC50 0.14 μM) were selected for determination of the mode of inhibition of Nek2, which was shown to be time-dependent, not reversed by addition of ATP and negated by site directed mutagenesis of Cys22 to alanine. Replacement of the ethynyl group by ethyl or cyano abrogated activity. Variation of substituents on the N-phenyl moiety for 6-ethynylpurines gave further SAR data for Nek2 inhibition. The data showed little correlation of activity with the nature of the substituent, indicating that after sufficient initial competitive binding to Nek2 subsequent covalent modification of Cys22 occurs in all cases. A typical activity profile was that for 2-(3-((6-ethynyl-9H-purin-2-yl)amino)phenyl)acetamide [IC50 0.06 μM (Nek2); GI50 (SKBR3) 2.2 μM] which exhibited >5-10-fold selectivity for Nek2 over other kinases; it also showed > 50% growth inhibition at 10 μM concentration against selected breast and leukaemia cell lines. X-ray crystallographic analysis confirmed that binding of the compound to the Nek2 ATP-binding site resulted in covalent modification of Cys22. Further studies confirmed that 2-(3-((6-ethynyl-9H-purin-2-yl)amino)phenyl)acetamide has the attributes of a drug-like compound with good aqueous solubility, no inhibition of hERG at 25 μM and a good stability profile in human liver microsomes. It is concluded that 6-ethynylpurines are promising agents for cancer treatment by virtue of their selective inhibition of Nek2. This journal is

Chemoselective Synthesis of Aryl Ketones from Amides and Grignard Reagents via C(O)-N Bond Cleavage under Catalyst-Free Conditions

Conversion of a wide range of N-Boc amides to aryl ketones was achieved with Grignard reagents via chemoselective C(O)-N bond cleavage. The reactions proceeded under catalyst-free conditions with different aryl, alkyl, and alkynyl Grignard reagents. α-Ketoamide was successfully converted to aryl diketones, while α,β-unsaturated amide underwent 1,4-addition followed by C(O)-N bond cleavage to provide diaryl propiophenones. N-Boc amides displayed higher reactivity than Weinreb amides with Grignard reagents. A broad substrate scope, excellent yields, and quick conversion are important features of this methodology.

I2-Catalyzed Oxidative Amidation of Benzylamines and Benzyl Cyanides under Mild Conditions

We report a novel and efficient method for the oxidation of benzylic carbons (amines and cyanides) into corresponding benzamides using a catalytic amount of I2 and TBHP as the green oxidant via the C-H bond cleavage of the benzylic carbon under mild reaction conditions. According to the literature survey, this is the first report for the oxidative amidation of benzylamines and decyanation of benzyl cyanides in one pot under metal-free conditions.

NOVEL LOW-MOLECULAR-COMPOUND FOR IMPROVING PRODUCTION, MAINTENANCE AND PROLIFERATION OF PLURIPOTENT STEM CELLS, COMPOSITION COMPRISING THE SAME, AND CULTURE METHOD

According to the present invention, when the novel low-molecular-weight compound RSC-133 is added in a culture process for producing reprogrammed pluripotent stem cells from human differentiated cells, it can increase the efficiency of reprogramming and c

NOVEL LOW-MOLECULE COMPOUND FOR PROMOTING PLURIPOTENT STEM CELL GENERATION, MAINTENANCE, AND PROLIFERATION, AND COMPOSITION AND CULTURING METHOD CONTAINING SAME

According to the present invention, when the novel low-molecular-weight compound RSC-133 is added in a culture process for producing reprogrammed pluripotent stem cells from human differentiated cells, it can increase the efficiency of reprogramming and c

Metal-free aryltrifluoromethylation of activated alkenes

Metal-free: The first metal-free aryltrifluoromethylation of activated alkenes has been developed. With this method, trifluoromethylated isoquinolinediones, spirobicycles, oxindoles, and α-aryl-β- trifluoromethylamides were obtained with high control of the regioselectivity. Copyright

NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE

The present invention relates to piperazine derivatives that act as inhibitors of stearoyl-CoA desaturase. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

ARYLUREA DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3, in particular inflammatory or obstructive airway diseases.

SUBSTITUTED SPIRO AZABICYCLICS AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present application describes modulators of CCR3 of formula (Ia) and (Ib): (I) or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5', R6, a, b

Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency

Starting with our previously described20 class of CC chemokine receptor-3 (CCR3) antagonist, we improved the potency by replacing the phenyl linker of 1 with a cyclohexyl linker and by replacing the 4-benzylpiperidine with a 3-benzylpiperidine. The resulting compound, 32, is a potent and selective antagonist of CCR3. SAR studies showed that the 3-acetylphenyl urea of 32 could be replaced with heterocyclic ureas or heterocyclic-substituted phenyl ureas and still maintain the potency (inhibition of eotaxin-induced chemotaxis) of this class of compounds in the low-picomolar range (IC50 = 10-60 pM), representing some of the most potent CCR3 antagonists reported to date. The potency of 32 for mouse CCR3 (chemotaxis IC50 = 41 nM) and its oral bioavailability in mice (20% F) were adequate to assess the efficacy in animal models of allergic airway inflammation. Oral administration of 32 reduced eosinophil recruitment into the lungs in a dose-dependent manner in these animal models. On the basis of its overall potency, selectivity, efficacy, and safety profile, the benzenesulfonate salt of 32, designated DPC168, entered phase I clinical trials.